Kathryn Schleckser Kayali

Kathryn Schleckser Kayali is a patent litigator at Williams & Connolly LLP, where she joined in 2016 following a clerkship with Judge Richard G. Taranto of the U.S. Court of Appeals for the Federal Circuit. Her practice is particularly focused on the pharmaceutical sector, encompassing litigation concerning both small-molecule and biologic drugs. Kayali primarily represents plaintiff operating companies, as evidenced by her three tracked appearances all on the plaintiff side, without any defendant-side engagements. Her work consistently involves complex pharmaceutical patent disputes, including cases for Regeneron Pharmaceuticals.

Kayali has played a significant role in several high-profile patent disputes for Regeneron Pharmaceuticals, Inc. She served as counsel in cases such as Regeneron Pharmaceuticals Inc. v. Unnamed Defendant, Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. et al., and Regeneron Pharmaceuticals, Inc. v. Formycon AG. These cases specifically involve patents related to Regeneron's biologic product EYLEA®, including the '865 patent for aflibercept formulations. Notably, a preliminary injunction granted against Formycon AG based on its biosimilar product was affirmed by the Federal Circuit in January 2025. She has experience handling pharmaceutical patent cases at every stage, from complaint through trial.

While her firm, Williams & Connolly, has noted success in PTAB proceedings, the provided information does not explicitly detail Kayali's direct appearances in Inter Partes Review (IPR) or Post Grant Review (PGR) proceedings. However, she has authored a publication titled "‘Reverse’ Patent Trolling: Nontraditional Participants in the Inter Partes Review Process," indicating familiarity with IPR procedures. Kayali earned her J.D. from Harvard Law School in 2014, an M.S. from The University of Texas at Dallas in 2011, and a B.A. cum laude from Yale University in 2009. She is admitted to practice in the District of Columbia and Massachusetts.